市场调查报告书
商品编码
1271789
下一代测序 (NGS) 市场——按产品、按应用、按类型、按技术、按最终用途和预测,2023-2032 年Next Generation Sequencing Market - By Product, By Application, By Type, By Technology, By End-use & Forecast, 2023 - 2032 |
由于其在各种製药和生物製药应用中的使用越来越多,预计到 2032 年,下一代测序 (NGS) 市场将出现显着增长。
拥有尖端生物技术解决方案的新兴经济体正在使用 NGS 进行药物发现和开发。 新疾病的出现和尚未确定治愈方法的终末期疾病的频繁发生,增加了对先进治疗方法的需求。 例如,NGS 已成为临床肿瘤学和癌症诊断的关键工具。 NGS能够以超高的灵敏度和精度检测突变,为癌症诊断和治疗提供突破。
视网膜母细胞瘤 (RB)、肺癌诊断等是 NGS 发展势头强劲的突出领域。 据美国癌症协会估计,到2023年,美国将有超过23.83万例肺癌新发病例和超过12.7万例死亡病例。 领先的生物技术和製药公司正在 NGS 的帮助下加速癌症诊断和治疗领域的创新和发展。
例如,2023 年 1 月,Thermo Fisher Scientific 宣布为用于治疗非小细胞肺癌患者的靶向抗癌药物 Tagrisso 设计基于固体组织和血液的伴随诊断 (CDx) 测试。与阿斯利康的合作伙伴关係。 两家公司将利用 Oncomine Dx Express Test,它具有智能样本到报告的工作流程,可使用完全集成的 NGS 平台 Genexus Dx 系统在 24 小时内提供测试结果。 因此,行业参与者之间更多的合作和新产品的发布将推动市场的增长。
按产品分类,它分为服务、设备、消耗品和其他。 其中,由于各种 NGS 服务的可用性,服务行业预计从 2023 年到 2032 年将以超过 18% 的复合年增长率增长。 最近在寡聚合成服务、全基因组测序、宏基因组学解决方案、癌症分析服务、RNA 测序等方面取得的突破使人们能够获得新的 NGS 服务。
按类型划分,市场分为靶向测序、全基因组测序 (WGS)、外显子组测序等。 预计在预测期内,靶向测序的需求将激增,因为它可以准确测量患者的基因库。 个性化疗法在治疗危及生命的疾病方面的日益普及进一步促进了靶向测序的使用,以研究个体的基因构成。
就最终用途而言,它分为製药/生物技术、学术机构/研究中心和医院/诊所。 到 2022 年,製药和生物技术公司的 NGS 市场规模将达到 10 亿美元。 製药公司开发先进疗法来应对复杂疾病的压力越来越大,这推动了 NGS 技术的采用。 世界各地的生物技术公司都依赖 NGS 来生产生物产品和新药。
按地区划分,由于印度和中国医疗基础设施建设取得进展,预计到 2032 年亚太地区 NGS 市场规模将超过 100 亿美元。 此外,基因组测序的成本、WGS 的技术进步以及亚太地区研发设施和研究中心的增加预计将推动该行业的增长。
Next-generation sequencing (NGS) market is set to witness substantial growth through 2032 owing to the increasing use of the technology for diverse pharmaceutical & biopharmaceutical applications.
Developed economies worldwide with state-of-the-art biotech solutions are using NGS for drug discovery and development. The emergence of novel diseases and the high prevalence of terminal illnesses with no promising cure have fueled the need for advanced therapies. For instance, NGS has emerged as a pivotal tool in clinical oncology and cancer diagnostics. It helps detect variants at an ultra-sensitive and precise level, offering groundbreaking cancer diagnosis and care.
Retinoblastoma (RB), and lung cancer diagnosis are some of the prominent areas where NGS has gained momentum. As per the American Cancer Society's 2023 estimates, the U.S. is projected to have more than 238,300 new cases of lung cancer and mortality of over 127,000 deaths. Leading biotech and pharma companies are accelerating innovation and development in the field of cancer diagnostics therapeutics with the help of NGS.
For instance, in January 2023, Thermo Fisher Scientific announced a partnership with AstraZeneca to design a solid tissue & blood-based companion diagnostic (CDx) test for Tagrisso, a targeted cancer drug used to treat patients with non-small cell lung cancer. The duo will use a fully-integrated NGS platform, Genexus Dx System to access the Oncomine Dx Express Test, featuring smart specimen-to-report workflow offering test results within 24 hours. As a result, a growing collaboration between industry players and new product launches will augment market growth.
In terms of product, the industry is classified into services, instruments, consumables, and others. Among these, the services segment will grow at over 18% CAGR between 2023 and 2032 led by the availability of a wide variety of NGS services. Recent breakthroughs in oligo synthesis services, whole genome sequencing, metagenomics solutions, cancer analysis services, RNA sequencing, and others are enabling access to novel NGS services.
Based on type, the market is segmented into targeted sequencing, whole genome sequencing (WGS), exome sequencing, and others. Targeted sequencing is set to witness an upsurge in demand over the forecast years due to its ability to measure a patient's gene pool precisely. The growing popularity of personalized therapeutics in the treatment of life-threatening diseases is further driving the use of targeted sequencing to study an individual's genetic makeup.
With regard to end-use, the industry is classified into pharmaceutical & biotech, academic institutes & research centers, and hospitals & clinics. NGS market size from pharmaceutical & biotechnology companies was USD 1 billion in 2022. The increasing pressure on pharma companies to develop highly advanced therapeutics to tackle complex disorders will fuel the adoption of NGS technologies. Biotech firms worldwide are using NGS to produce biological goods and novel pharmaceuticals.
From a regional frame of reference, the Asia Pacific NGS market size will exceed USD 10 billion by 2032 due to the rise in healthcare infrastructure development across India, and China. Additionally, promising cost of genome sequencing, technological breakthroughs in WGS, and the increasing number of R&D facilities and research centers in APAC will propel industry growth.